Focus: Medacta is a Swiss-based orthopedic implant manufacturer specializing in knee and hip arthroplasty systems, serving the global musculoskeletal market as a publicly listed company founded in 1999.
Profile data last refreshed 4h ago · AI intelligence enriched 1mo ago
Stable — net +2 jobs in 30d
2 added, 0 removed. Backfill posture.
Medacta represents a stable, niche orthopedic device player suitable for professionals seeking established market position over explosive growth, but current hiring freeze and data opacity warrant caution.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Flagship knee arthroplasty system with proprietary medial-pivot design and customized instrumentation platform.
Help build intelligence for Medacta
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Medacta's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Unicompartmental knee arthroplasty addressing partial joint degeneration with less invasive approach.
Core hip acetabular component with multiple configurations (standard, double mobility, 3D metal) supporting diverse surgical approaches.
Hip stem system with cementless fixation options for primary and revision procedures.
Based on last 4 crawl cycles
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo